

**CALL OF THE ORDINARY GENERAL MEETING OF ONCOMATRYX  
BIOPHARMA, S.A.**

In Derio (Bizkaia), 15 May 2026

Dear shareholder,

You are hereby called to the ordinary general meeting of Oncomatryx Biopharma, S.A. (the "**Company**"), to be held on June 16, 2026, at 12:30 p.m., at the registered office, i.e., in Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B- 2º (postal code 48160), without prejudice to allowing both physical attendance at the registered office and attendance by telematic means under the protection of the provisions of the Spanish Companies Act and article 15 of the Company's bylaws, with the following:

**AGENDA**

- First. -** General information on the progress of the Company.
- Second. -** Approval of the Company's individual and consolidated annual accounts, corresponding to the year ended December 31, 2025.
- Third. -** Approval of the Company's corporate management, corresponding to the year ended December 31, 2025.
- Fourth. -** Application of the Company's result, corresponding to the year ended December 31, 2025.
- Fifth. -** Approval of the maximum remuneration of the managing director.
- Sixth. -** Determination of the fixed remuneration of the managing director.
- Seventh. -** Delegation of faculties.
- Eighth. -** Drafting, reading and, where appropriate, approval of the minutes of the Meeting.

**Right to information.** Shareholders have the right to examine at the registered office, located in Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B-2º (postal code 48160) or request the delivery or free sending of a copy (which may be sent by email with acknowledgement of receipt if the shareholder accepts this means) of the following documents:

1. Full text of the proposed resolutions corresponding to the items on the agenda, submitted by the Board of Directors; and
2. The Company's individual and consolidated annual accounts for the 2025 financial year, as well as any other document that is mandatory to submit to the General Meeting of the Company for approval.

Similarly, in accordance with the provisions of Article 197 of the Spanish Companies Act, until the seventh day prior to the day scheduled for the holding of the general meeting, shareholders may request from the board of directors the information or clarifications they deem necessary regarding the matters included in the agenda, or to ask in writing the questions they consider pertinent.

During the holding of the general meeting, the shareholders of the Company may verbally request the information or clarifications they deem appropriate regarding the matters included in the agenda.

**Right to supplement the agenda.** In accordance with the provisions of Article 15 of the Company's bylaws and Article 172 of the Spanish Companies Act, shares representing at least 5% of the share capital may request that a supplement to the call for the general shareholders' meeting be published by including one or more items on the agenda.

The exercise of this right must be done by means of reliable notification that must be received at the registered office within 5 days of the publication of the call. The supplement to the call must be published at least 15 days before the date set for the meeting of the general meeting.

**Right of attendance.** In accordance with the provisions of Article 19 of the Company's bylaws, the holders of shares who have them registered in the register of registered shares 5 days prior to the date on which the general meeting is to be held and the holders of shares who prove by means of a public document their regular acquisition of the shares of who appears as shareholder in the register of registered shares will have the right to participate with voice and vote.

**Telematic attendance.** In accordance with the provisions of Article 15 of the Company's bylaws, it will be possible to attend the General Shareholders' Meeting by videoconference. By virtue of this, the link to access the meeting will be sent to all shareholders, by means of individual communication to the e-mails included in the Company's databases. In the event that any shareholder wishes to be sent the *link* to another email, they must state this and contact the Company by e-mail [shareholders@oncomatryx.com](mailto:shareholders@oncomatryx.com), including proof of their status as a shareholder at least 5 days before the date of the meeting.

Shareholders who wish to attend the General Meeting electronically may participate and cast their vote in the same way, in accordance with the following specifications and instructions:

- The videoconference will be held using the Microsoft Teams platform that allows telematic attendance of all shareholders who wish to do so.
- To access the videoconference, it will be necessary to download the Microsoft Teams computer platform on the computer, mobile phone or other electronic devices equipped with a webcam and audio.
- Prior to the videoconference, an internet link will be provided, via email, to be able to join it.

**Right of representation.** In accordance with the provisions of Article 19 of the Company's bylaws, any shareholder who has the right to attend may be represented by another person, even if he or she is not a shareholder. The proxy must be granted in writing and on a special basis for each general meeting. Any shareholder may exercise their right of representation through the proxy card, the model of which will be included on the Company's website ([www.oncomatryx.com](http://www.oncomatryx.com)) from the date of the call to the General Shareholders' Meeting. The proxy must be completed and signed by the shareholder, signing the corresponding proxy card. The proxy must be accepted by the shareholder's representative, without which it cannot be exercised. To this end, the representative must also sign the proxy card. The representative in whose favour the proxy is conferred must exercise it by personally

attending the General Shareholders' Meeting, handing over the proxy card, at the place and day set for the holding of the General Shareholders' Meeting and from one hour before the scheduled time for the start of the meeting. Likewise, the proxy cards may be delivered during the days prior to the Meeting at the registered office, Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B- 2º (postal code 48160) or may be sent by the shareholder to the following email address [shareholders@oncomatryx.com](mailto:shareholders@oncomatryx.com).

**Vote by mail.** In accordance with the provisions of Article 19 of the Company's bylaws, shareholders may exercise their voting rights by post, electronic correspondence or any other means of remote communication. To cast a postal vote, the shareholder must complete and sign the voting card, the model of which will be included on the Company's website ([www.oncomatryx.com](http://www.oncomatryx.com)), in which they will state their vote – in favour or against – the abstention or blank vote, marking with a cross in the corresponding box.

The completed and signed card must be sent to Oncomatryx Biopharma, S.A. by post addressed to Derio (Bizkaia), Parque Tecnológico de Vizcaya, 801-B- 2º (postal code 48160) or by email addressed to the President at the following e-mail [shareholders@oncomatryx.com](mailto:shareholders@oncomatryx.com). A shareholder who casts his vote by correspondence and does not have a mark in any or all of the boxes intended to indicate the vote on the items on the agenda, will be understood to wish to vote in favour of the respective proposals made by the Board of Directors.

The vote cast by correspondence shall be null and void by subsequent and express revocation by the shareholder, carried out by the same means used for the issuance and within the period established for the issue, or by the personal attendance at the General Shareholders' Meeting of the shareholder who has cast the vote by correspondence or by the attendance of his representative.

The vote cast by mail must be received by the Company before 11:59 p.m. on the day prior to the General Shareholders' Meeting, i.e. before 11:59 p.m. on June 16, 2026. Otherwise, the vote will be understood as not cast. After the aforementioned period, only votes cast at the General Shareholders' Meeting by the shareholder or by the shareholder validly representing him or her will be admitted. A shareholder who casts his or her vote remotely by correspondence will be considered as present for the purposes of the constitution of the General Shareholders' Meeting.

**Delegation and vote in the event of a complement to the call.** If, as a result of the exercise of the right to include new items on the agenda corresponding to shareholders representing at least 5% of the share capital, a supplement to this call is published, shareholders who have delegated their proxy or who have cast their vote before the publication of said supplement may:

- (a) Confer the proxy again with the corresponding voting instructions or to cast the vote again, with respect to all the items on the agenda (including both the initial items and the new items incorporated through the supplement), in which case the proxy granted or the vote cast previously will be deemed revoked and will be null and void; or
- (b) Complete the corresponding voting instructions to the initially designated representative (who must be the same and no other may be appointed) only with respect to the new items on the agenda incorporated by means of the supplement, all in accordance with the procedures and methods mentioned in the previous sections and by the same means used in the proxy conferred or the vote originally cast.

In the event that the shareholder has cast the remote vote before the publication of the supplement and does not carry out any of the actions indicated under sections (a) and (b) above, it will be understood that he abstains with respect to said new points.

Derio, May 15, 2026. By the Board of Directors, the secretary non-director, Mr. Luis Alba Ferré.